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Building, Leicester Royal Infirmary, Leicester LE2 7LX, UKThis paper was published in 1999 and was one of the first of
a series of reports from the EUROSTAR collaborators. It
showed the importance of robust registry data for new
procedures such as EVAR and subsequently proved to be the
best of the endovascular registries. The mortality in the
series was 3.2% which was very acceptable at the time. The
key message was that freedom from endoleak was associ-
ated with aneurysm sac shrinkage, whereas persistent
endoleak may lead to sac expansion and rupture. In addi-
tion, the authors highlighted the importance of screening
for endoleak (pre-discharge and during follow-up) and also
the need for bail out options to deal with a variety of intra
and postoperative problems.
Following EUROSTAR, several trials of endovascular
aneurysm repair were conducted and the UK contribution was
the EVAR1 and EVAR2 trials. These showed that in fit patients
[EVAR1] endovascular repair was superior to open repair and
that this benefit was sustained out to 4 years. In contrast, the
EVAR2 trial showed that endovascular repair did not confer
any advantage over best medical therapy. The classification
of endoleaks became widely adopted and a distinction was
made between dangerous high pressure endoleaks [Type 1
and Type 3] which require further intervention to prevent
aneurysm rupture and low pressure endoleaks [Type 2] whose
clinical relevance remains uncertain.
With hindsight, this paper had a number of weaknesses
including short follow-up [6.2 months] and the lack of
available data at 18 months [45%]. Another issue was the
retrospective nature of the early data in the study which
was then combined with prospective data later on.
It is also of interest to note how practise has changed.
The 7% aortic tube graft insertion rate is historical and the
median size of aneurysm was only 55 mm, with a size rangeDOI of original article: 10.1053/ejvs.1999.0836.
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rysms persists. Most patients underwent follow-up with CT
scanning and this was the mode of follow-up in the EVAR
trials, but since then duplex scanning has gradually
replaced CT in many centres. This removes the risk of
radiation exposure and the nephrotoxic risks of contrast
media. Several papers have shown that duplex is as good as
CT scanning, particularly if type 2 endoleaks are ignored.
As expected, the EUROSTAR registry contained a large
number of devices which are no longer in use. The data also
highlighted the importance of careful case selection,
particularly as the conversion rate was 2% and the device
failed to deploy in 26 out of 899 patients. Eighteen of these
26 were converted to open repair. The procedure and device
related problems together with the access site/arterial
complications are higher than would be expected nowadays.
So where are we now? The EVAR trials have shown the
robustness of EVAR versus open repair in fit patients.
However, the recent 8 year results suggest that late
endograft rupture remains a problem and that this may be
related to complications such as endoleak which the
EUROSTAR registry addressed but also graft migration
which they did not. The natural history of endoleaks
remains uncertain although it is widely accepted that
endoleaks may come and go. In addition, the trend is
towards more conservative management of type 2 endo-
leaks and the recognition that any form of treatment of
type 2 endoleak (such as injection of Thrombin, lumbar
vessel clipping and embolisation via the SMA or internal
iliacs) is difficult and may not achieve success. The rele-
vance of increasing sac size with type 2 endoleak also
remains confusing.
The final problem with the early EVAR papers is that the
new generation of devices are not associated with many of
the early problems seen, although the major issue facing
EVAR at the present time is understanding the pathophysi-
ology of late endograft rupture.d by Elsevier Ltd. All rights reserved.
